Program
cemiplimab
Also written as “Cemiplimab”, “REGN2810” and “REGN2810/chemo/ipi”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Melanoma · Carcinoma, Basal Cell · Squamous Cell Carcinoma of Head and Neck · Neoplasm Metastasis, led by 7 companies.
Drug pageCemiplimab: every studyMany companies study it; this page follows only the 42 they lead. All 135 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Regeneron Pharmaceuticalsits history only | 3516 open or running | phase 3since Mar 3, 2017 | Feb 2, 2015 | Mar 22, 2027phase 3 · NCT06246916 |
| BioNTechits history only | 20 open or running | phase 2since Apr 21, 2020 | Apr 21, 2020 | none ahead |
| Maia Biotechnologyits history only | 11 open or running | phase 3since Mar 20, 2025 | Mar 20, 2025 | Jul 31, 2027phase 3 · NCT06908304 |
| Merck KGaA, Darmstadt, Germany | 10 open or running | phase 2since May 22, 2023 | May 22, 2023 | none ahead |
| Sanofiits history only | 10 open or running | phase 2since Jun 19, 2017 | Jun 19, 2017 | none ahead |
| SillaJenits history only | 10 open or running | phase 2since Sep 19, 2017 | Sep 19, 2017 | none ahead |
| Vyriadits history only | 11 open or running | phase 2since Feb 25, 2020 | Feb 25, 2020 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Merck KGaA, Darmstadt, Germany only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 9, 2018Named cemiplimabINNProposed as its International Nonproprietary Name in WHO's List 119 · before, REGN2810
- May 22, 2023First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT05882734 · 61 enrolled · United States, Belgium, France and more
TargetBeta
“Programmed cell death protein 1 inhibitor”ChEMBL 37, by rule
Other programs on PDCD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| tivunatamig | Pfizer | phase 3 | 15 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| pucotenlimabrule | taizhou-hanzhong-biomedical-co-ltd | phase 3 | 15 |
| enlonstobartrule | CSPC Pharmaceutical Group | phase 3 | 15 |
| ezabenlimab | Boehringer Ingelheim | phase 3 | 13 |
| Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363rule | Innovent Biologics | phase 3 | 10 |
| rulonilimabrule | Lunan Pharmaceutical Group | phase 3 | 9 |
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 4 |
Studies
The one study Merck KGaA, Darmstadt, Germany leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05882734Carcinoma, Non-Small-Cell Lung · United States, Belgium, France and more | 2 | Completed | Jul 15, 2026 | 61 |
How it is read
Names in the registry
- “Cemiplimab”, 23 entries
- “cemiplimab”, 9 entries
- “REGN2810”, 4 entries
- “REGN2810/chemo/ipi”, 2 entries
- “Fianlimab+cemiplimab”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 9 studies
- Melanoma, 7 studies
- Carcinoma, Basal Cell, 3 studies
- Squamous Cell Carcinoma of Head and Neck, 1 study
- Neoplasm Metastasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.